echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > J Bone Miner Res: Study on the effect of zoledronate after denosumab in the treatment of osteoporosis

    J Bone Miner Res: Study on the effect of zoledronate after denosumab in the treatment of osteoporosis

    • Last Update: 2022-01-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In patients who discontinued denosumab (DMAB), bone turnover increased rapidly, and the increased bone mass was lost over 12 to 24 months over the course of treatment
    .
    DMAB is a fully human IgG2 monoclonal antibody that neutralizes the receptor activator of nuclear factor kappa-B ligand (RANKL)


    .


    We investigated the long-term efficacy of zoledronate (ZOL) in maintaining bone mineral density (BMD) after discontinuation of denosumab
    .
    In this randomized, open-label interventional study, we included 61 postmenopausal women and men over 50 years of age who discontinued denosumab after 4.


    6±1.


    After discontinuing long-term DMAB, some ZOL patients were treated with three different regimens and re-treated in the first year, and their BMD was maintained within the premenopausal reference interval in the second year, and CTX was stable within the premenopausal reference interval
    .
    After 24 months of treatment, the mean bone loss in the spine was 4.


    2% and the mean bone loss in the total hip was 3.


    Source: Sølling AS, Harsløf T, Langdahl B, Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study, J Bone Miner Res 2021 Jul;36(7) 

    Sølling AS, Harsløf T, Langdahl B, Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study, J Bone Miner Res 2021 Jul;36(7) 

     

     

     

     

     

    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.